Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer

APMIS

Volumn 117, Issue 10, 2009, Pages 755-761

  Almasi, Charlotte Elberling ^a   HØyer Hansen, Gunilla ^a   Christensen, Ib Jarle ^a   Pappot, Helle ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Cleaved uPAR; Non small cell lung cancer; Prognosis; Time resolved fluoroimmunoassay; UPAR; UPAR domain I

Indexed keywords

UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN DOMAIN;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUOROIMMUNOASSAY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 70349324792     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02533.x     Document Type: Article

References (35)

1. Hirsch FR, Bunn PK Jr., Kato H, Mulshine JL. Global Epidemiology of Lung Cancer. In: IASLC. Textbook of Prevention and Detection of Early Lung Cancer, Chapter 1. Abingdon, UK : Taylor & Francis 2006.
2. Rajdev L, Keller SM. Neoadjuvant and adjuvant therapy of non-small cell lung cancer. Surg Oncol 2002 11 : 243 253.
3. Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol 2008 3 : 84 93.
4. Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer - the smoke clears. N Engl J Med 2005 352 : 2640 2642.
5. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005 93 : 676 681.
6. Behrendt N, Rønne E, Danø K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996 271 : 22885 22894.
7. Høyer-Hansen G, Behrendt N, Ploug M, Danø K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997 420 : 79 85.
8. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997 243 : 21 6.
9. Høyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Danø K, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 2001 358 : 673 679.
10. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000 57 : 25 40.
11. Høyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007 44 : 65 102.
12. Rømer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004 10 : 2359 2376.
13. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007 25 : 5287 5312. (Pubitemid 350232263)
14. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002 94 : 116 128.
15. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994 344 : 401 402.
16. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995 1 : 1079 1087.
17. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994 54 : 4671 4675.
18. Plebani M, Herszenyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 1997 15 : 418 425.
19. Cobos E, Jumper C, Lox C. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin Appl Thromb Hemost 2003 9 : 241 246.
20. Pappot H, Høyer-Hansen G, Rønne E, Hansen HH, Brünner N, Danø K, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997 33 : 867 872. (Pubitemid 27287037)
21. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002 8 : 1132 1141.
22. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999 91 : 869 874.
23. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007 25 : 349 355.
24. Rasch MG, Lund IK, Almasi CE, Høyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008 13 : 6752 6762.
25. Almasi CE, Høyer-Hansen G, Christensen IJ, Danø K, Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005 48 : 349 355.
26. Mountain CF, Lukeman JM, Hammar SP, Chamberlain DW, Coulson WF, Page DL, et al. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 1987 35 : 147 156.
27. Piironen T, Laursen B, Pass J, List K, Gårdsvoll H, Ploug M, et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004 50 : 2059 2068.
28. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brünner N, et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006 52 : 838 844.
29. Fietz T, Hattori K, Thiel E, Heissig B. Increased soluble urokinase plasminogen activator receptor (suPAR) serum levels after granulocyte colony-stimulating factor treatment do not predict successful progenitor cell mobilization in vivo. Blood 2006 107 : 3408 3409.
30. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997 15 : 398 408.
31. Pappot H. The plasminogen activation system in lung cancer - with special reference to the prognostic role in "non-small cell lung cancer". APMIS Suppl 1999 92 : 1 29.
32. Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP, et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 2000 11 : 327 332.
33. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator- receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004 24 : 4147 4161.
34. Cho WC. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007 61 : 515 519.
35. D'Amico TA. Molecular biologic staging of lung cancer. Ann Thorac Surg 2008 85 : S737 42.